Biomedical Research Infrastructure Goes Global

Six institutions from Canada, the Czech Republic, Austria, France and Italy have now become official partners of the Infrafrontier consortium. With the participation of Canada, the consortium will be extended beyond Europe. The aim is to create a multinational research infrastructure for the phenotyping and archiving of mouse models of human diseases.

Helmholtz Zentrum München today announced that the Infrafrontier project, funded by the European Union, has been expanded to include six partners from Canada, the Czech Republic, Austria, France and Italy. The new partners will join the effort of the other 22 members of Infrafrontier in building up an international research infrastructure to improve open access to high-quality mouse models. Animal models have become an important tool in the study of complex human diseases such as diabetes, osteoporosis, asthma and depression, but also in the study of fundamental mechanisms such as speech development in humans. Colin McKerlie, spokesman of the Canadian partner, views the partnership as a "crucial step to successfully face one of the most interesting scientific challenges of the 21st century; to understand the function of every gene in the genome."

Professor Martin Hrabé de Angelis is director of the Institute of Experimental Genetics at Helmholtz Zentrum München and coordinates the EU Project Infrafrontier. "The international expansion facilitates the networking of the best scientists across the globe," Martin Hrabé de Angelis said. This opportunity is especially important to the Czech partners, as Prof. Radislav Sedlacek, programme coordinator for the Czech Center for Phenogenomics, stressed.

"We know that in the coming years we will be confronted with scientific tasks that cannot be solved with the infrastructure we currently have in Europe," Hrabé de Angelis went on to say. Infrafrontier will close this gap by expanding existing facilities and building new ones. A central coordination unit shall also be established. These endeavors will provide biomedical research with an international, open-access research infrastructure.

The partners in the Infrafrontier Consortium are the leading European systemic phenotyping centers (mouse clinics), the members of EMMA (European Mouse Mutant Archive) and research ministries and major funding agencies. New to Infrafrontier are the Czech Center for Phenogenomics and the Czech Republic's Ministry for Education, Youth and Sport, the Veterinary University of Vienna, the French institute INSERM (Institut National de la Santé et de la Recherche Médicale), the Italian Ministry of Labor, Health and Social Sciences and the Toronto Center for Phenogenomics. Altogether, 12 European countries and Canada now participate in Infrafrontier.

Infrafrontier is part of the ESFRI (European Strategy Forum on Research Infrastructures) roadmap, which outlines a plan to create research infrastructures of great scientific importance and pan-European interest, and which is therefore funded by the European Union.

For further information, please visit:
http://www.infrafrontier.eu

Most Popular Now

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

New Antibiotic Targets IBD - and AI Pred…

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...